NASDAQ:PRTA Prothena Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. $27.77 +0.23 (+0.84%) (As of 06/24/2022 06:55 PM ET) Add Compare Share Today's Range$26.06▼$27.8650-Day Range$22.73▼$35.7852-Week Range$21.06▼$79.75Volume709,800 shsAverage Volume446,364 shsMarket Capitalization$1.30 billionP/E Ratio22.76Dividend YieldN/APrice Target$70.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Stock Forecast (MarketRank)Overall MarketRank™2.66 out of 5 starsMedical Sector71st out of 1,411 stocksPharmaceutical Preparations Industry23rd out of 672 stocksAnalyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.00, Prothena has a forecasted upside of 155.7% from its current price of $27.77.Amount of Analyst CoverageProthena has only been the subject of 1 research reports in the past 90 days. Previous Next 4.8 Community Rank Outperform VotesProthena has received 578 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProthena has received 222 “underperform” votes. (Add your “underperform” vote.)Community SentimentProthena has received 72.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote “Outperform” if you believe PRTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have bought 8,180.47% more of their company's stock than they have sold. Specifically, they have bought $30,840,599.00 in company stock and sold $372,450.00 in company stock.Percentage Held by Insiders31.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.64% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($2.53) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is 22.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is 22.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 15.72.Price to Book Value per Share RatioProthena has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prothena (NASDAQ:PRTA)Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.Read More PRTA Stock News HeadlinesJune 22, 2022 | finance.yahoo.comProthena Corporation plc's (NASDAQ:PRTA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?June 20, 2022 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Receives $67.89 Average Target Price from BrokeragesJune 18, 2022 | americanbankingnews.comProthena (NASDAQ:PRTA) Stock Price Down 10%June 16, 2022 | thestreet.comCramer's Mad Money Recap 6/15: Powell Crushes it - TheStreetJune 10, 2022 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Forecasted to Post FY2023 Earnings of ($3.89) Per ShareJune 9, 2022 | nasdaq.comWhy Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report? - NasdaqJune 5, 2022 | americanbankingnews.comProthena (NASDAQ:PRTA) Trading Up 2.1%June 2, 2022 | benzinga.comProthena to Participate in Jefferies Healthcare Conference - Benzinga - BenzingaJune 2, 2022 | finance.yahoo.comProthena to Participate in Jefferies Healthcare ConferenceJune 2, 2022 | americanbankingnews.comShort Interest in Prothena Co. plc (NASDAQ:PRTA) Expands By 31.2%May 25, 2022 | benzinga.comJMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $50 - Benzinga - BenzingaMay 8, 2022 | finance.yahoo.comThese Analysts Just Made A Massive Downgrade To Their Prothena Corporation plc (NASDAQ:PRTA) EPS ForecastsMay 7, 2022 | apnews.comProthena: Q1 Earnings SnapshotSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees82Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/27/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$71.00 High Stock Price Forecast$103.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+153.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$1.22 Trailing P/E Ratio22.76 Forward P/E RatioN/A P/E GrowthN/ANet Income$66.97 million Net Margins33.45% Pretax Margin32.76% Return on Equity16.02% Return on Assets11.93% Debt Debt-to-Equity RatioN/A Current Ratio15.22 Quick Ratio15.22 Sales & Book Value Annual Sales$200.58 million Price / Sales6.48 Cash Flow$1.58 per share Price / Cash Flow17.54 Book Value$10.00 per share Price / Book2.78Miscellaneous Outstanding Shares46,806,000Free Float32,203,000Market Cap$1.30 billion OptionableOptionable Beta1.37 Prothena Frequently Asked Questions Should I buy or sell Prothena stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prothena stock. View analyst ratings for Prothena or view top-rated stocks. What is Prothena's stock price forecast for 2022? 7 analysts have issued 1 year price objectives for Prothena's stock. Their PRTA stock forecasts range from $14.00 to $103.00. On average, they expect Prothena's share price to reach $71.00 in the next year. This suggests a possible upside of 155.7% from the stock's current price. View analysts' price targets for Prothena or view top-rated stocks among Wall Street analysts. How has Prothena's stock price performed in 2022? Prothena's stock was trading at $49.40 at the start of the year. Since then, PRTA shares have decreased by 43.8% and is now trading at $27.77. View the best growth stocks for 2022 here. When is Prothena's next earnings date? Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Prothena. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.07. The biotechnology company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.23 million. Prothena had a net margin of 33.45% and a trailing twelve-month return on equity of 16.02%. View Prothena's earnings history. Who are Prothena's key executives? Prothena's management team includes the following people: Dr. Gene G. Kinney Ph.D., Pres, CEO & Director (Age 53, Pay $1.02M)Mr. Tran B. Nguyen M.B.A., CFO & Chief Strategy Officer (Age 48, Pay $745.35k)Mr. Brandon S. Smith, Chief Operating Officer (Age 47, Pay $648.34k)Ms. Carol D. Karp, Chief Regulatory Officer (Age 69, Pay $679.3k) (LinkedIn Profile)Dr. Hideki Garren M.D., Ph.D., Chief Medical Officer (Age 57, Pay $859.64k)Ms. Karin L. Walker C.P.A., CPA, Chief Accounting Officer & Controller (Age 59) (LinkedIn Profile)Dr. Wagner M. Zago, Chief Scientific Officer (Age 49)Ms. Jennifer Zibuda, Director of Investor Relations & CommunicationMr. Michael J. Malecek, Chief Legal Officer (Age 56) (LinkedIn Profile)Dr. Radhika Tripuraneni M.P.H., M.D., Chief Devel. Officer (Age 42) Who are some of Prothena's key competitors? Some companies that are related to Prothena include Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Cytokinetics (CYTK), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Zai Lab (ZLAB) and Bausch Health Companies (BHC). View all of PRTA's competitors. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." Who are Prothena's major shareholders? Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.26%), State Street Corp (5.06%), First Light Asset Management LLC (3.93%), Palo Alto Investors LP (3.59%), Dimensional Fund Advisors LP (3.22%) and Vanguard Group Inc. (1.87%). Company insiders that own Prothena stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke and Wagner M Zago. View institutional ownership trends for Prothena. Which institutional investors are selling Prothena stock? PRTA stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Citigroup Inc., Healthcare of Ontario Pension Plan Trust Fund, TD Asset Management Inc., Massachusetts Financial Services Co. MA, First Trust Advisors LP, Vanguard Group Inc., and Federated Hermes Inc.. Company insiders that have sold Prothena company stock in the last two years include Carol D Karp, Christopher S Henney, Dennis J Selkoe, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke, and Wagner M Zago. View insider buying and selling activity for Prothena or view top insider-selling stocks. Which institutional investors are buying Prothena stock? PRTA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Paradigm Biocapital Advisors LP, First Light Asset Management LLC, Sessa Capital IM L.P., Renaissance Technologies LLC, Prosight Management LP, Capital Fund Management S.A., and Mariner LLC. View insider buying and selling activity for Prothena or or view top insider-buying stocks. How do I buy shares of Prothena? Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $27.77. How much money does Prothena make? Prothena (NASDAQ:PRTA) has a market capitalization of $1.30 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or $1.22 on an earnings per share basis. How many employees does Prothena have? Prothena employs 82 workers across the globe. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for Prothena is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at [email protected], or via fax at 353-1902-3510. This page (NASDAQ:PRTA) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here